Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.
Also called NCT03183245
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 242 participants
- Registry
-
NCT03183245
-
- Other papers using this trial's data
- Bioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: a multicentre, randomised, controlled, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03183245. Randomized; no masking; primary purpose treatment. Start 2017-09-29 (actual); primary completion 2024-04-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
- Condition
- Renal Failure
- Condition
- End Stage Renal Disease
- Condition
- Hemodialysis
- Condition
- Vascular Access
- Intervention (Biological)
- Human Acellular Vessel (HAV)
- Intervention (Procedure)
- Arteriovenous fistula (AVF)
- Intervention (Other)
- Hemodialysis
- Lead sponsor
- Humacyte, Inc.
- Collaborator
- CTI Clinical Trial and Consulting Services
- Collaborator
- California Institute for Regenerative Medicine (CIRM)
Record details
- Record id
cardio:ct-nct03183245- Content hash
a87ddf0589faf476c792f0bfce8b1ed7fd50c230bebe5120c90c6f79b06744b0